PepGen posts positive Phase 2 data for FREEDOM2-DM1 at 10 mg/kg
PEPG•PEPG•PEPG•PEPG•PepGen reported 46.5% mean splicing correction after four monthly doses of PGN-EDODM1, while video hand opening time improved 3.9 seconds, or 52.7%, from baseline at week 16. The company said treatment was generally well tolerated.
PepGen reported positive results from the 10 mg/kg cohort of its Phase 2 FREEDOM2-DM1 study. After four monthly doses of PGN-EDODM1, mean splicing correction was 46.5%; video hand opening time improved 3.9 seconds, or 52.7%, from baseline at week 16. The company said functional improvements were observed across multiple measures, with no serious or severe adverse events or dose-limiting toxicities reported.
PepGen expects interim clinical data at 5 mg/kg and safety data at 10 mg/kg from an open-label extension study in January 2027. Results from the FREEDOM2 12.5 mg/kg cohort are expected in the first half of 2027.
